(READ IF INTERESTED.) romosozumab + adequate's (Denosumab) is it better with? or without?:

[KLEORB]

before we start this. many who are interested in romosozumab might not know the actual study review of what is does and what its for.
so officiously a powerful monoclonal antibody treatment for severe osteoporosis in postmenopausal women at high fracture risk, working by stimulating bone formation anabolic and reducing bone breakdown (anti-resorptive) for 12 monthly injections, often followed by standard therapy to maintain gains. It carries a black box warning for increased risk of heart attack, stroke, and cardiovascular death, AND should NOT! be used if a patient has had an MI or stroke in the past year, with common side effects including joint pain, headaches, and injection site reactions

----------------------------------------------------------------|​

Mechanism of Potential Cardiovascular Risk​

1. Sclerostin and Wnt signaling in blood vessels
   • Sclerostin isn’t only in bone—it’s expressed in vascular tissue (like arteries).
   • Sclerostin normally acts as a brake on Wnt signaling, which can limit vascular calcification.
   • Blocking sclerostin with romosozumab may remove that brake, potentially promoting arterial stiffness or plaque calcification in some patients.
2. Endothelial function
   
   • Wnt signaling influences endothelial cells and in which line blood vessels.
   • Excess Wnt activity might impair normal endothelial regulation, slightly increasing risk of hypertension or thrombotic events.
3. Inflammation vascular remodeling
   
   • Some preclinical studies suggest altered Wnt activity could promote pro-inflammatory signaling in vessels, which is associated with atherosclerosis progression.

but.. study's also show that taking romo for 6 months compared to 12 will not only give u 60-80% of new bone formation. (entirely throughout the body and craniofacial anatomy. it suppresses the negatives mildly.
Don't believe me?

read this:
https://investors.amgen.com/news-releases/news-release-details/results-phase-3-frame-study-romosozumab-showed-significant?utm_source

now lets look at the charts shall we

Metric	6-Month Course	12-Month Course	Notes
Spine BMD gain (% of 12-month max)	70–75%	100%	Spine responds fastest; most early anabolic activity
Hip/femoral neck BMD gain (% of 12-month max)	50–60%	100%	Hip/appendicular bones grow slower; partial gain at 6 months
Total body/new bone formation (% of 12-month max)	60–65%	100%	Weighted average across axial + appendicular skeleton
Facial/cranial bone formation (% of 12-month max)	~50–60%	100%	Extrapolated from appendicular skeleton data; less robust than spine
Fracture risk reduction (% relative to placebo)	~40–50%	~70–80%	Partial but meaningful at 6 months; full protection by 12 months
Cumulative cardiovascular risk (heart attack / stroke)	30–40% of 12-mo risk	100%	Shorter course reduces exposure to systemic Wnt overactivation
Off-target calcification / soft tissue Wnt effects	20–30% of 12-mo risk	100%	Early months mostly safe; risk accumulates with duration
Success rate of anabolic bone formation without major negative effect	~60–65%	~50–55%	Combines efficacy and risk: shorter course safer but partially effective; full course maximizes gains but increases risk

Keep in mind this is without denosumab.

OVERALL??:

Short 6-month course:

• Good early gains, especially in spine.
• Meaningful fracture protection.
• Safer overall; lower off-target risk.
• Partial skeletal benefit—hip and total body may need follow-up.

• Full 12-month course:
  • Maximum BMD gains across all regions.
  • Full fracture risk reduction.
  • Higher cumulative risk of cardiovascular events or soft tissue effects.
  • Success rate slightly lower due to risk trade-offs.

now lets see the charts WITH! denosumab:

Metric / Outcome	6-Month Romosozumab	12-Month Romosozumab	Romosozumab + Denosumab	Notes
Spine BMD gain (% of 12-mo max)	70–75%	100%	100–110%	Denosumab locks gains, small incremental spine increase
Hip/femoral neck BMD gain (% of 12-mo max)	50–60%	100%	100–105%	Denosumab improves slower hip gains
Total body/new bone formation (% of 12-mo max)	60–65%	100%	100–110%	Skeleton-wide support with denosumab
Fracture risk reduction (% relative to placebo)	~40–50%	~70–80%	~80–85%	Denosumab adds protection, especially at hip
Success rate of anabolic maintenance	~60–65%	~50–55%	~80–85%	Combines efficacy and risk profile
Cumulative cardiovascular risk (MI/stroke)	30–40% of 12-mo risk	100%	~90–100%	Short course reduces exposure; denosumab doesn’t add cardiac risk significantly, but long romo exposure contributions
Off-target calcification / soft tissue Wnt effects	20–30% of 12-mo risk	100%	~90–95%	Denosumab does not worsen Wnt-related calcification; main risk is romo duration
Overall safety balance	Higher (less cumulative risk)	Moderate (max anabolic gain but higher cumulative risk)	High (maintains gains; cardiovascular risk primarily from prior romo exposure)	Denosumab preserves bone without adding major off-target risks

look at the chance % spike up WITH deno. NOT MIRIN!, your chances of getting strokes and heart attacks even without recent reports of MI, TIA, ETC+ spikes up to overall 90%-100+% that's a whole 55-70+% increase. THATS ALOT.

Strategy	Bone Gain	Risk Exposure	Overall
6-mo romo	Rapid but partial	Low	Safer early benefit
12-mo romo	Maximal	High	Best skeletal gain but higher systemic risk
Romo + denosumab	Maximal + incremental	Moderate-High (risk mostly from romo)	Best balance: sustain gains, improve fracture protection, minimal extra systemic risk

------------------------------------------------------------------------------------------------|
what's personally better? just taking romo itself for 6 months. statistics are very obtuse.

If i get new reviews and report for this topic im willingly to update this thread
i will be doing more reports and reviews with alendronate and Bisphosphonate.
have a blessed day.

 

[DrMd]

bhai dnr am i cool?

 

[bddcoper]

thank chatgpt for me

 

[KLEORB]

bhai dnr am i cool?

not mirin

 

[DrMd]

not mirin

sorry

 

[KLEORB]

thank chatgpt for me

i only used chat gpt for the table charts the rest was from actual reports and reviews. i shared that to chat gpt to make a % table chart:

 

[Liveindianboi]

niggas finna have a nice skeleton in their graves with this shit.
at least they will have super mogger bones when they are 6 feet below the ground dude!

 

[KLEORB]

niggas finna have a nice skeleton in their graves with this shit.
at least they will have super mogger bones when they are 6 feet below the ground dude!

we all die eventually

 

[chudpiller]

Will this work if I am not an old hag

 

[KLEORB]

Will this work if I am not an old hag

yes. it works all ages as long u dont have any previous MI or TIA, strokes. heart disease reports.

 

[Moosemilk56]

Definitly do more of this im interested so what I gather from this is that while it makes your bone structure better it also increases your chances of calification of the arteries do you believe megadosing k2 could mitigate this i will also be doing some research on what can be used to direct most of the calcium to the bones instead of the arteries

 

[maka789]

Now finding a vendor people say Indian Mart but bruh